Hi GLA,
Thank you - It is a very quiet thread, but I would expect that if the thread was active, then the SP would be considerably higher.
Yes, I did focus on a revenue comparison (versus EBIT) as this was an easier metric to communicate. Some of the peer group capitalises Research & Development (AZV expenses R&D) and they reside in different jurisdictions with different accounting standards (eg GAAP versus AABS).
In essence the re-structuring process entailed closing down Perth based manufacturing and shifting across to Dallas, USA manufacturing. The difference is cost base is substantial - it the order of $AUD28 / hour (fully loaded costs) versus closer to $USD12 / hours (full loaded). However, this triggered substantial redundancy costs and parallel of production lines, resulting in an interruption of supply lines over this time period - virtually impossible to shift manufacturing from one country to another with causing a level of delays. Understanding this process, I waited until the transition was complete, but prior to the full cost benefits to trickle down to the bottom line - hence the timing of my investment.
Additionally, the company divested a non-core asset (CellGuard), which generated a decrease in revenues as a result, but enabled the company to focus on its core, healthcare interests. A prudent decision, but resulted in a loss of revenue from this segment.
I have every confidence with the re-structuring (having done exactly the same process in my own electronics business in 2007, which operating in an identical market segment). I have known the business for 30 years, so I have a pretty good understanding of the segment
I would expect that in FY19, the Company will likely get back to a 15%-18% EBITDA, in line with its peer group.
The company has a history of not communicating to shareholders particularly well, however I suspect that the board would be hesitant to spend funds on Investor Relations until such time as the transition was complete, all the one-off costs incurred and written off, to provide a clean slate moving forward.
- Forums
- ASX - By Stock
- AHC
- Azure Healthcare Revisited
AHC
austco healthcare limited
Add to My Watchlist
1.67%
!
29.5¢

Azure Healthcare Revisited, page-3
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
29.5¢ |
Change
-0.005(1.67%) |
Mkt cap ! $107.3M |
Open | High | Low | Value | Volume |
29.5¢ | 30.5¢ | 29.5¢ | $190.1K | 633.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 33045 | 29.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
30.5¢ | 2921 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 33045 | 0.295 |
4 | 196654 | 0.290 |
1 | 3509 | 0.285 |
1 | 36000 | 0.280 |
1 | 15000 | 0.275 |
Price($) | Vol. | No. |
---|---|---|
0.305 | 2921 | 1 |
0.310 | 70511 | 4 |
0.315 | 170744 | 3 |
0.320 | 300726 | 4 |
0.330 | 230000 | 1 |
Last trade - 15.29pm 07/07/2025 (20 minute delay) ? |
Featured News
AHC (ASX) Chart |
The Watchlist
AGC
AUSTRALIAN GOLD AND COPPER LTD
Glen Diemar, MD
Glen Diemar
MD
SPONSORED BY The Market Online